Key facts
- LoQus23 Therapeutics’s last known valuation is $61.4M.
- It has raised $67.2M; the latest was Later Stage VC ($46.3M) in Oct 2024.
- Notable investors include SV Health Investors, Forbion, Novartis Venture Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for LoQus23 Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for LoQus23 Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LoQus23 Therapeutics
Developer of allosteric small molecule inhibitors targeting MSH3/MutSbeta designed to treat Huntington's disease and other triplet repeat neurodegenerative disorders. The company's therapeutics modulate the DNA mismatch repair pathway to address the underlying genetic mechanisms of these conditions, enabling the development of disease-modifying treatments for patients with repeat expansion-driven neurodegeneration.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2019
- Employees
- 9
- Website
- loqus23.com/
- Ownership
- Privately Held (backing)
LoQus23 Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LoQus23 Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LoQus23 Therapeutics in its N-PORT filings yet. We sweep new filings monthly.